Corresponding Author: Gregory D. Lewis, MD, Division of Cardiology, GRB 800, Department of Medicine, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (glewis@partners.org).
Accepted for Publication: January 28, 2020.
Published Online: March 17, 2021. doi:10.1001/jamacardio.2021.0292
Author Contributions: Drs Shah and Lewis had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Shah and Armengol de la Hoz and Mr Schoenike contributed equally.
Concept and design: Schoenike, Armengol de la Hoz, Blodgett, Kowal, Malhotra, Vasan, Lewis.
Acquisition, analysis, or interpretation of data: Shah, Schoenike, Armengol de la Hoz, Cunningham, Tanguay, Sbarbaro, Nayor, Rouvina, Houstis, Baggish, Ho, Hardin, Malhotra, Larson, Vasan, Lewis.
Drafting of the manuscript: Shah, Schoenike, Armengol de la Hoz, Cunningham, Sbarbaro, Rouvina, Kowal, Vasan, Lewis.
Critical revision of the manuscript for important intellectual content: Shah, Schoenike, Blodgett, Tanguay, Nayor, Houstis, Baggish, Ho, Hardin, Malhotra, Larson, Vasan.
Statistical analysis: Shah, Schoenike, Armengol de la Hoz, Cunningham, Sbarbaro, Malhotra.
Obtained funding: Shah, Vasan, Lewis.
Administrative, technical, or material support: Schoenike, Blodgett, Tanguay, Rouvina, Kowal, Houstis, Hardin, Vasan.
Supervision: Nayor, Ho, Hardin, Vasan.
Conflict of Interest Disclosures: Dr Shah reported grants from National Institutes of Health (NIH) and American Heart Association during the conduct of the study; personal fees from MyoKardia and Best Doctors; grants from Amgen; stocks in Pfizer and Gilead Sciences outside the submitted work; and has patent for extracellular RNAs and cardiac remodeling issued. Dr Ho reported grants from NIH during the conduct of the study; grants from Gilead Sciences and Bayer; and research supplies from EcoNugenics outside the submitted work. Dr Malhotra reported consulting fees from MyoKardia and Third Pole Therapeutics and ownership interest from Patch outside the submitted work. Dr Vasan reported grants from NIH during the conduct of the study and is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Lewis reported grants from NIH, American Heart Association, Amgen, Cytokinetics, Applied Therapeutics, Cyclerion Therapeutics, SoniVie, and AstraZeneca; personal fees from AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Edios, American Regent, and UpToDate; and has served as a scientific advisor for Merck and Relypsa outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (contracts N01-HC-25195, HHSN268201500001I, and 75N92019D00031), the National Institutes of Health (grants K23-HL138260 [Dr Nayor], R01HL134893 [Dr Ho], R01HL140224 [Dr Ho], 1R01HL131029 [Drs Vasan and Lewis], R01HL151841 [Drs Lewis and Shah]), American Heart Association (grant 15GPSGC24800006 [Dr Lewis]), and Amgen (Dr Lewis).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the dedication of the Framingham Heart Study participants and Massachusetts General Hospital Exercise Study participants without whom this research would not be possible.